2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4208 A next-generation BCL-2 inhibitor lisaftoclax-integrated flu-bu-cy conditioning for high-risk myeloid neoplasms undergoing allogeneic hematopoietic stem cell transplantation: A pilot study

Dan Feng, MD, Pan Pan2, Xianjing Zhang3, Rongli Zhang4, Jialin Wei5, Erlie Jiang, MD6
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, China

Background:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative therapy for patients with high-risk myelodysplastic syndromes (MDS) and related myeloid neoplasms. However, transplant-related mortality and post-transplant relapse remain major barriers to long-term survival. Therefore, strategies to enhance the antitumor activity of conditioning regimens without increasing transplant-related toxicity represent an unmet clinical need. The BCL-2 pathway plays a critical role in the survival of malignant myeloid clones and resistance to apoptosis. Venetoclax, a selective BCL-2 inhibitor, has demonstrated clinical activity in MDS, particularly when combined with hypomethylating agents or chemotherapy; however, its application is limited by myelosuppression, infectious complications, and the development of resistance mechanisms. Lisaftoclax (APG-2575), a novel second-generation selective BCL-2 inhibitor, provides a promising opportunity to integrate targeted apoptosis induction into the conditioning platform for allo-HSCT.

Methods:
We conducted a pilot study enrolling patients with high-risk MDS and related myeloid neoplasms who underwent allo-HSCT at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, between September 3, 2025, and June 1, 2026. Eligible patients had high-risk or very high-risk disease according to IPSS-R or IPSS-M criteria. Eighteen patients were enrolled, with a median age of 52 years (range, 30–72); 15 patients were aged ≥50 years, and 3 were considered unfit for intensive therapy due to age, comorbidities, or disease status.

All patients received a lisaftoclax-integrated Flu-Bu-Cy myeloablative conditioning regimen. Lisaftoclax was administered using a step-up dosing schedule, with 200 mg on day -11, 400 mg on day -10, and 600 mg daily from day -9 to day -3. During this period, busulfan (3.2 mg/kg/day) was administered on days -7 to -5, fludarabine (30 mg/m²/day) on days -4 to -2, and cyclophosphamide (40 mg/kg/day) on days -2 and -1. The primary objectives were to evaluate the feasibility, safety, and early transplant outcomes of incorporating lisaftoclax into the conditioning platform.

 

 

Results:
Eighteen patients were enrolled, including 16 patients with MDS and 2 with chronic myelomonocytic leukemia (CMML). The median age was 52 years (range, 30–72), and 13 patients (72.2%) had a significant comorbidity burden, including cardiovascular diseases, diabetes mellitus, hypertension, or autoimmune disorders. The most frequent myeloid-related mutations included ASXL1 (27.8%), U2AF1 (27.8%), and RUNX1 (22.2%). All patients successfully completed allo-HSCT following lisaftoclax-integrated Flu-Bu-Cy myeloablative conditioning. All patients achieved neutrophil engraftment within 28 days, with median neutrophil and platelet engraftment times of 19 days (range, 11–21) and 22 days (range, 12–49), respectively. Grade 3–4 adverse events occurred in 5 patients (27.8%), including bacteremia (n=3), diarrhea (n=1), and intracranial hemorrhage (n=1). The 100-day cumulative incidence of grade II–IV acute GVHD was 46.5%, and the 200-day cumulative incidence of chronic GVHD was 39.2%.

At the data cutoff of July 31, 2026, with a median follow-up of 6.5 months, 17 patients were alive, and the 200-day overall survival rate was 86.2%. One patient developed morphological relapse at 3 months after transplantation, while two additional patients showed molecular evidence of persistent or recurrent disease, including persistent NPM1 positivity and emergence of MLL-PTD positivity at 4.5 months after transplantation.

Conclusion:
Integration of the next-generation BCL-2 inhibitor lisaftoclax into Flu-Bu-Cy conditioning was feasible and associated with manageable toxicity in patients with high-risk MDS and related myeloid neoplasms undergoing allo-HSCT. Early disease control was observed, supporting further prospective evaluation of BCL-2-targeted conditioning strategies.

Dan Feng, MD: No relevant conflicts of interest to declare.